ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papa Silvia, D'Alto Michele, Scelsi Laura, Acquaro Mauro, Adamo Francesca, Albera Carlo, Ameri Pietro, Argiento Paola, Badagliacca Roberto, Carignola Renato, Casu Gavino, Confalonieri Marco, Corda Marco, Correale Michele, Cresci Chiara, D'Alessandro Francesca, D'Agostino Carlo, De Caterina Raffaele, De Michele Lucrezia, De Tommasi Elisabetta, Di Marino Serena, Filomena Domenico, Galgano Giuseppe, Garascia Andrea, Giannazzo Daniela, Greco Alessandra, Grimaldi Massimo, Lanzarone Nicola, Lattanzio Mariangela, Lombardi Carlo Mario, Madonna Rosalinda, Maggio Enrico, Manzi Giovanna, Mercurio Valentina, Mihai Alexandra, Mulè Massimiliano, Orlando Antonio, Paciocco Giuseppe, Pezzuto Beatrice, Piccinino Cristina, Poscia Roberto, Raineri Claudia, Recchioni Tommaso, Romaniello Antonella, Romeo Emanuele, Serino Giorgia, Serra Walter, Stolfo Davide, Tricarico Lucia, Vatrano Marco, Vitulo Patrizio, Vizza Carmine Dario, Ghio Stefano, Italian Pulmonary Hypertension NETwork (iPHNET)
Аннотация
METHODS: Twenty-six PAH centers were initially involved in the registry. Data were collected on anthropometric measurements, medical history, vital signs, clinical signs of heart failure, physical examination, laboratory tests (hematology and clinical chemistry), WHO functional class evaluation, non-encouraged 6-min walk test (6MWT), echocardiographic imaging and right heart catheterization (RHC) of outpatients and inpatients with PAH (Group 1) diagnosis. All the centers shared a common database for the prospective follow-up of the patients.
RESULTS: between May 2014 and January 2023, a total of 500 prevalent patients with clinical diagnosis of PAH were enrolled: idiopathic (40.6 %), heritable (4.6 %), associated with drug or toxins (0.8 %), associated with connective tissue disease (26.4 %), associated with HIV infection (4.8 %), associated with portal hypertension (3.8 %), associated with congenital heart disease (16,4 %), with features of venous/capillary involvement (1.4 %), others (1.2 %) were enrolled. According to the ERS/ESC guidelines risk assessment, 207 (41.4 %) patients were at low risk, and 286 (57.2 %) were at intermediate risk. According to the REVEAL 2.0 score, 352 (70.4 %) patients were at low risk (score < 7), 93 (18.6 %) were at intermediate risk (score 7-8), and 55 (11 %) were at high risk (score > 8), Of the total patient population, 177 (35.4 %) received monotherapy, 222 (44.4 %) received double combination therapy, and 101 (20.2 %) received triple combination therapy.
CONCLUSION: Built as a collaborative registry of centers treating PAH patients in Italy, it holds significant promise for addressing several critical needs within the field, including patients' clinical trajectory and risk stratification.